Lupin Ltd - nicht nehmen, doppelt Headquartered in Mumbai, India, our company today is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world. Dr. Desh Bandhu Gupta’s vision and dream to fight life threatening infectious diseases and manufacture drugs of highest national priority led to the formation of the company in the year 1968. His Vision, his inimitable commitment and verve have steered it to achieving the distinction of becoming one of the fastest growing Generic players globally. The company first gained recognition when it became one of the world’s largest manufacturers of Tuberculosis drugs. Over the years, it has moved up the value chain and has not only mastered the business of intermediates and APIs, but has also leveraged its strengths to build a formidable formulations business globally. In FY 2011, net sales grew by 20% to INR 57,068 Mn up from INR 47,736 Mn the previous year. EBITDA margins increased to 20% and net profits grew at 27% to INR 8,626 Mn compared to INR 6,816 Mn in FY 2010. Standing on the shoulders of our past performance record, these results deliver some of the best growth numbers in the industry - 27% CAGR in Gross Sales; 32% CAGR in EBITDA and 38% CAGR in PAT, for the last 6 years.